%PDF-1.4
%
59 0 obj
<>
endobj
56 0 obj
<>
endobj
109 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-07-08T19:06:35Z
2024-03-29T04:53:08-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-29T04:53:08-07:00
application/pdf
Heather
2002-709.aug
uuid:012887f6-1dd2-11b2-0a00-6b08271d5700
uuid:012887f9-1dd2-11b2-0a00-bf0000000000
endstream
endobj
45 0 obj
<>
endobj
46 0 obj
<>
endobj
60 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 31 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 33 0 R/Type/Page>>
endobj
9 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 35 0 R/Type/Page>>
endobj
17 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 37 0 R/Type/Page>>
endobj
25 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 39 0 R/Type/Page>>
endobj
127 0 obj
[131 0 R]
endobj
128 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc -0.00031 Tw 10 0 0 10 54 713.1616 Tm
[(toms may be quite prevalent in fibromyalgia syndrome. )17.7 (The)]TJ
0.11259 Tw 0 -1.2 TD
(health care practitioner should be aware of these potential)Tj
0.0551 Tw T*
[(manifestations of FM. )17.7 (The underlying mechanisms respon-)]TJ
0.1286 Tw T*
(sible for the chronic pain in FM may have an association)Tj
0.1163 Tw T*
(with mechanisms responsible for oral pain and/or salivary)Tj
0.27921 Tw T*
(dysfunction. Further research into these oral conditions,)Tj
0.0652 Tw T*
(objective criteria for their measurement, and elucidation of)Tj
0.02499 Tw T*
(pathophysiologic mechanisms is warranted.)Tj
/T1_1 1 Tf
0 Tw 0 -2.4 TD
(REFERENCES)Tj
/T1_0 1 Tf
0.02499 Tw 8 0 0 8 61 595.1616 Tm
[(1.)-875.1 (Giovengo SL, Russell IJ, Larson )54.8 (A. Increased concentrations of)]TJ
1.675 -1.25 Td
(nerve growth factor in cerebrospinal fluid of patients with )Tj
0 -1.25 TD
(fibromylagia. J Rheumatol 1999;26:1564-9.)Tj
-1.675 -1.275 Td
[(2.)-875.1 (Granges G, Littlejohn G. Pressure pain threshold in pain-free)]TJ
1.675 -1.275 Td
(subjects, in patients with regional pain syndromes and in patients)Tj
0 -1.275 TD
[(with fibromyalgia syndrome. )54.8 (Arthritis Rheum 1993;36:21-8.)]TJ
-1.675 -1.275 Td
[(3.)-875.1 (W)79.9 (olfe F)79.7 (, Smythe HA, )36.8 (Y)110.8 (unus MB, et al. )17.7 (The )54.8 (American College of)]TJ
1.675 -1.275 Td
(Rheumatology criteria for the classification of fibromyalgia: report)Tj
T*
[(of the Multicenter Criteria Committee. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1990;33:160-72.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(4. )-600.1 (Slavkin H. Chronic disabling diseases and disorders. J )54.8 (Am Dent)]TJ
0 Tc 1.675 -1.25 Td
(Assoc 1997;128:1583-9.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(5.)-875.1 (Rhodus NL. Xerostomia and glossodynia in patients with )]TJ
1.675 -1.25 Td
[(autoimmune disorders. Ear Nose )17.7 (Throat J 1989;68:791-4.)]TJ
-1.675 -1.25 Td
[(6.)-875.1 (Dinerman H, Goldenber)17.7 (g D, Felson DT)73.9 (. )54.8 (A)-220.1 (prospective evaluation)]TJ
1.675 -1.25 Td
[(of 1)36.8 (18 patients with fibromyalgia syndrome. J Rheumatol)]TJ
0 Tc 0 Tw 0 -1.25 TD
(1986;13:368-72.)Tj
-0.00011 Tc 0.02499 Tw 31.325 35.096 Td
[(7.)-875.1 (T)35 (ishler M, Barak )36.8 (Y)128.9 (, Paran D, )36.8 (Y)99.8 (aron M. Sleep disturbances,)]TJ
1.675 -1.25 Td
[(fibromyalgia and primary Sj\232gren\325)54.8 (s syndrome. Clin Exp Rheumatol)]TJ
0 Tc 0 Tw T*
(1997;15:71-4.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(8.)-875.1 (Bonafede RP)110.7 (, Downey DC, Bennett RM. )54.8 (An association of)]TJ
1.675 -1.25 Td
[(fibromyalgia with primary Sj\232gren\325)54.8 (s syndrome: )54.8 (A)-220.1 (prospective study)]TJ
T*
(of 72 patients. J Rheumatol 1995;22:133-7.)Tj
-1.675 -1.25 Td
[(9.)-875.1 (Barton )54.8 (A, Pal B, )17.7 (Whorwell PJ, Marshall D. Increased prevalence of)]TJ
1.675 -1.25 Td
(sicca complex and fibromyalgia in patients with irritable bowel)Tj
T*
[(syndrome. )54.8 (Am J Gastroenterol 1999;94:1898-901.)]TJ
-2.175 -1.25 Td
[(10.)-875.1 (Y)99.8 (avuz S, Fresko J, Hamuryudan )17.7 (V)128.9 (,)-0.1 ( )36.8 (Y)110.8 (urdakul S, )36.8 (Y)99.8 (azici H.)]TJ
2.175 -1.25 Td
[(Fibromyalgia in Beh\215et\325)54.8 (s syndrome. J Rheumatol 1998;25:2219-23.)]TJ
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Heir GM. Dif)17.7 (ferentiation of orofacial pain related to L)54.8 (yme disease)]TJ
2.1381 -1.25 Td
[(from other dental and facial pain disorders. Dent Clin North )54.8 (Am)]TJ
0 Tc 0 Tw T*
(1997;41:243-58.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(12.)-875.1 (Fricton JR. )54.8 (Atypical orofacial pain disorders: a study of diagnostic)]TJ
2.175 -1.25 Td
(subtypes. Curr Rev Pain 2000;4:142-7.)Tj
-2.175 -1.25 Td
[(13.)-875.1 (Plesh O, )17.7 (W)79.9 (olfe F)79.7 (, Lane N. )17.7 (The relationship between fibromyalgia)]TJ
2.175 -1.25 Td
(and temporomandibular disorders: prevalence and symptom)Tj
0 Tc T*
[(severity)64.9 (. J Rheumatol 1996;23:1948-52.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(14.)-875.1 (Rhodus NL. Detection and management of the dental patient with)]TJ
0 Tc 2.175 -1.25 Td
[(Sj\232gren\325)54.9 (s syndrome. Compendium 1987;8:578,580,582.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(15.)-875.1 (Rhodus NL. Sj\232gren\325)54.8 (s syndrome. Quintessence Int 1999;30:689-99.)]TJ
T*
[(16.)-875.1 (Hudson JI, Harrison GP)110.7 (. Fibromylagia and psychopathology: Is)]TJ
2.175 -1.25 Td
[(fibromyalgia a form of \322af)17.7 (fective spectrum disorder?\323 J Rheumatol)]TJ
0 Tc 0 Tw T*
(1989;36:15-21.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(17.)-875.1 (Dubner R. Neuronal plasticity and pain following peripheral tissue)]TJ
2.175 -1.25 Td
[(inflammation or nerve injury)64.8 (. In: Bond MR, Charlton JE, )17.7 (W)79.9 (oolf CJ,)]TJ
T*
[(editors. Proceedings of the )17.7 (VIth )17.7 (W)79.9 (orld Congress on Pain, 1991.)]TJ
T*
(Amsterdam: Elsevier Science Publishers; 1991:263-76.)Tj
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_2 1 Tf
8 0 0 8 54.5 35.9844 Tm
(Rhodus, et al: Oral symptoms in FM)Tj
0 Tc 0 Tw 60.9375 -0.0313 Td
(1845)Tj
ET
0 0 0 0 k
/GS0 gs
109.22 59.09 396.48 -10.84 re
f*
0.5 w
109.22 59.09 396.48 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_3 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
39 0 obj
<>stream
8;Z\7!KP&?%.jK`R.&gP1pQ"3.1pdP8b"iY*K\2d$*.4&n?7@4`!lOU@+Q?@%;jj7
#/7;7&bapsM9lcQ2#lF2+sO[DqS_nL7_O%&3.%>^=Y@S)jk)0ED<+?@o-'"QXHe
j(j-_CcFN"HD*.Hbc*KlPLcnX[!qG[>K.)n#c"qPA313)'EfTH!q;.6T+Wq8Y,nu\
*IGD>J="h\:pKIq,5H.;L72M/S.a&OWKdI^/djQ_dqT/ce&hlM\44$u$unL19A2ti
K/%2=7/0#EgS>fpf&_^X42.]/TD@!e+p8c*Xp:g3&V;5dgh$b#WapZ+3&d\kn>'=W
L_TrMG*M#`E3c$1i)>3_q!ADX2<\9oD+^q@G2=]h!V:WXfY7L7j2q_>LZ
n7_u2H!M/d]&DP)N3>RA:ad"bKgMJ0./Z64O!@+0(6>_9_6p2l9gA;eS&
endstream
endobj
43 0 obj
[/Indexed/DeviceRGB 255 42 0 R]
endobj
42 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
67 0 obj
<>
endobj
28 0 obj
<>
endobj
62 0 obj
<>
endobj
98 0 obj
<>
endobj
114 0 obj
<>
endobj
63 0 obj
<>
endobj
90 0 obj
<>stream
HyTSw^,O(yeTDVRm ,RQb$@@ @ 1ɢpUZPQc;Sp̙ιw~w|.YZ`8۹ymu_+K6+B$acpBs-8Ga8̷X'-9:Z^HZo,SߺjL#q.kwv^^DD*ae]W,j-\*f
Tn&ņ(N,ŎX\g>'f%r6UĆ!{YnSOPEYlȾXVb+CpIHD,WM'cs0l.- 1
#0[yc{{9doect%[)&<:ZnU4 9ϓeB~)'AԅS_OKGYۄ4ڮgB˦?
Kӗ
dô:{\M{N*(2/QJI5Exi<19)L&9^átJwF;̠lh0L9
Ҍ&#^}.4
ZVwأ9!Krb_˙`
U`}.v#]K.b LUJfG_*~T
iADp
mIrr9bG3I*Br
#p1́9VkBF5E]f6-= OE:? [WPurWRM;XmH!`NzT՜=Y=j